Expanded Experience with Ultra-Short Duration Pangenotypic Direct Acting Anti-Viral (DAA) Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic (HCV) Donors to Hepatitis C Negative Kidney Transplant Recipients (KT).

被引：0
|
作者：
Yakubu, I. [1 ]
Kumar, D. [1 ]
Sharma, A. [1 ]
Levy, M. [1 ]
Kamal, L. [1 ]
Gupta, G. [1 ]
机构：
[1] Virginia Commonwealth Univ, Richmond, VA USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2022年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
554
引用
收藏
页码：573 / 573
页数：1
相关论文
共 28 条
  • [21] Direct Acting Anti-Viral (DAA) Therapy for Chronic Hepatitis C Virus (HCV) Infection Is Associated with Regression of Liver Fibrosis, Assessed by Serial Transient Elastography (Fibroscan)
    Chan, Justin
    Gogela, Neliswa
    Zheng, Hui
    Lammert, Sara
    Ajayi, Tokunbo
    Fricker, Zachary
    Kim, Arthur Y.
    Robbins, Gregory K.
    Chung, Raymond T.
    HEPATOLOGY, 2016, 64 : 395A - 396A
  • [22] The Use of Sofosbuvir (SOF)-containing Direct Antiviral Agents (DAA)-based Regimens Requires Increase in Tacrolimus (Tac) Doses in Kidney Transplant (KT) Recipients with Hepatitis C Virus (HCV) Infection
    Polanco, Natalia
    Fernandez, Mario
    Garcia, Ana
    Munoz, Raquel
    Trujillo, Hernando
    Sevillano, Angel
    Gonzalez, Esther
    Maria Aguado, Jose
    Praga, Manuel
    Andres, Amado
    TRANSPLANTATION, 2018, 102 : S228 - S228
  • [23] ACCIDENTAL TRANSMISSION OF HEPATITIS C (HCV) VIRUS FROM AN ORGAN DONOR TO FIVE TRANSPLANT RECIPIENTS: EARLY TREATMENT WITH DIRECT ACTING ANTIVIRALS SUCCESSFULLY PREVENTS CHRONIC HCV INFECTION
    Halleck, Fabian
    Budde, Klemens
    Hofmann, Joerg
    Eisenberger, Ute
    Herzer, Kerstin
    Stemeck, Martina
    Gottlieb, Jens
    Schulz, Uwe
    Duerr, Michael
    TRANSPLANT INTERNATIONAL, 2017, 30 : 37 - 38
  • [24] ACCIDENTAL TRANSMISSION OF HEPATITIS C (HCV) VIRUS FROM AN ORGAN DONOR TO FIVE TRANSPLANT RECIPIENTS: EARLY TREATMENT WITH DIRECT ACTING ANTIVIRALS SUCCESSFULLY PREVENTS HCV-INFECTION
    Duerr, M.
    Budde, K.
    Hofmann, J.
    Eisenberger, U.
    Herzer, K.
    Sterneck, M.
    Gottlieb, J.
    Schulz, U.
    Halleck, F.
    TRANSPLANT INTERNATIONAL, 2017, 30 : 28 - 28
  • [25] The Use of Sofosbuvir (SOF)-Containing Direct Antiviral Agents (DAA)-Based Regimens Requires Increase in Tacrolimus (Tac) Doses in Kidney Transplant (KT) Recipients with Hepatitis C Virus (HCV) Infection.
    Fernandez, N. Polanco
    Santiago, A. Garcia
    Ruiz, M. Fernandez
    Munoz, R.
    Vazquez, C. Alvarez
    Hernandez, A.
    Mercado, V.
    Monte, E. Gonzalez
    Fernandez, I.
    Aguado, J.
    Praga, M.
    Andres, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 230 - 231
  • [26] Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients An Open-Label Nonrandomized Trial
    Durand, Christine M.
    Bowring, Mary G.
    Brown, Diane M.
    Chattergoon, Michael A.
    Massaccesi, Guido
    Bair, Nichole
    Wesson, Russell
    Reyad, Ashraf
    Naqvi, Fizza F.
    Ostrander, Darin
    Sugarman, Jeremy
    Segev, Dorry L.
    Sulkowski, Mark
    Desai, Niraj M.
    ANNALS OF INTERNAL MEDICINE, 2018, 168 (08) : 533 - +
  • [27] TREATMENT OF HEPATITIS C RECURRENCE POST LIVER TRANSPLANT WITH ORAL DIRECT ACTING ANTI-VIRAL: A REAL-WORLD EXPERIENCE FROM A SATELLITE CLINIC IN THE SOUTHERN UNITED STATES
    Trieu, Richard
    Henderson, Phillip
    Idriss, Rajab
    HEPATOLOGY, 2021, 74 : 605A - 605A
  • [28] Incidence of Deterioration of HepaticFunction Despite of Sustained Virological Response (SVR) From Direct Acting Anti-Hepatitis C Viral (HCV) Therapy in Post Liver Transplant (Ltx) Recipients: Possible Etiological Factors, Management and Prevention.
    Liao, Xiaojie
    Tian, Ye
    Kadry, Zakiyah
    Krok, Karen
    Riley, Thomas
    Schreibman, Ian
    Jain, Ashokkumar
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 76 - 76
123